Samsara BioCapital, LLC holds a concentrated book of 22 stocks worth $1.0B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Spyglass Pharma Inc and trimmed X4 Pharmaceuticals Inc. Their largest long position is Scholar Rock Holding Corp at 33% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Samsara BioCapital, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| UBS Group AG | 23 / 22 | $685.5M |
| MORGAN STANLEY | 23 / 22 | $416.8M |
| GOLDMAN SACHS GROUP INC | 23 / 22 | $412.3M |
| MILLENNIUM MANAGEMENT LLC | 22 / 22 | $252.1M |
| BlackRock, Inc. | 21 / 22 | $1.4B |
| GEODE CAPITAL MANAGEMENT, LLC | 21 / 22 | $427.6M |
| BARCLAYS PLC | 21 / 22 | $48.9M |
| FMR LLC | 20 / 22 | $1.4B |
Ranked by how many of Samsara BioCapital, LLC's top 22 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1744967/holdings"
Use Arkolith to show Samsara BioCapital, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.